Good News

America leads the world in curing disease. We have entered an unprecedented age of scientific advancement: First gene and cell therapies commercialized, record FDA approvals, wave of transformative genomic cures in the clinic, IPOs and venture investment are strong.

Bad News

It could all collapse in the blink of an eye. We face unprecedented political danger as leaders from both parties champion policies that would disincentivize investment and kill innovation in the name of lowering drug prices.
DRIVING ANTI-INDUSTRY CRITICISM

Conflation of List Price & Patient Out-of-Pocket Costs

Manufacturer’s Retail List Price ≠
46% of voters believe it’s **MOST IMPORTANT** for policymakers to lower what people pay out of pocket for medicines, compared to less than one-third who said lowering list prices was important.

Indeed, **76%** of voters support limiting what seniors pay out of pocket under the Medicare Part D prescription drug program.

Voters chose increased competition over government-imposed price controls by a **2 TO 1 MARGIN** when asked about the best way to lower drug costs.

Nearly **70%** of voters are **LESS LIKELY** to support drug pricing legislation if it leads to less access to medicines.
Drug Costs Only Part of Health Spend Going Down

While health care prices rose 1.5% in August 2019 over August 2018, drug prices fell by -.7% in that span.

The 12-month moving average for drug prices was -.4% in July – the lowest rate since 1972.

Source: Altarum analysis of monthly BLS data.
OUR TWO MORAL IMPERATIVES

1) Patients should never go without the medicine they need because they can’t afford what comes out of their pocket.

2) We must expand access to treatment in ways that don’t kill innovation for patients still waiting for their cure.
Bipartisan Agreement:
Capping Seniors Out-of-Pocket Costs

- DTC requirement to include list price in ads
- PBM reforms
- Capping out-of-pocket drug costs for seniors
- Reforming Part D catastrophic coverage
- Addressing obstacles to generic uptake

Trump Administration

House Democrats
- Foreign reference pricing in Medicare
- Foreign reference pricing in Medicare and commercial markets

Senate Finance
- Government price-setting
How Does Impeachment Impact Patients & Innovation?
WELCOMES AMY WALTER
National Editor of The Cook Political Report